Phaseline

Targets › MURAA

MURAA: drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 4, 2 Phase 3; Infectious disease, Other; next expected readout Sep 2027.

Open in Phaseline: the race on MURAA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Meitheal PharmaceuticalsFosfomycin (ZTI-01)
UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor
MURAAPhase 4Healthy Lactating Women; Infections, Bacterial; Gram Negative Infections; Urinary Tract InfectionsSep 2027

Conditions

Healthy Lactating Women (1) Infections, Bacterial (1) Gram Negative Infections (1) Urinary Tract Infections (1)

Modalities

small molecule (1)

Companies

Meitheal Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.